



CR-UK STRATIFIED MEDICINE PROGRAMME and Technology Strategy Board Projects

Mike Griffiths

West Midlands Regional genetics Laboratory
Birmingham Women's NHS Foundation Trust

Birmingham United Molecular Pathology

Collaborating since 2004



West Midlands Regional Genetics Laboratory (WMRGL)
Birmingham Women's Hospital

Largest UK NHS genetic laboratory

>48,000 samples per annum

>140 staff

60% constitutional; 40% cancer related

Central England Haemato-oncology Research Biobank



Department of Cellular Pathology (DCP)
University Hospitals Birmingham

Largest Trust and Cell Path in WM region

16 consultant histopathologists and >50 biomedical scientific and other staff


Integrates with Human Biomaterials Resource Centre

Cancer Research UK's Stratified Medicine Programme

Together we will beat cancer



Two organisations, four funding areas – all aimed at improving stratified medicine in cancer

	Funding areas	Funds to
 CANCER RESEARCH UK	Molecular diagnostics	Labs (NHS & private) "Technology Hubs"
	Sample & data collection	ECMCs (hospitals) "Clinical Hubs"
Technology Strategy Board Driving Innovation	Panel assay development	Collaborations incl. samples, labs
	Data solution development	Collaborations incl. data, hospitals


On- size-fits-all (or not)

Same type of cancer



Same type of treatment

Stratified (personalised) Medicine




CR-UK Stratified Medicine Programme

- To develop a cost effective strategy (target £300/patient) to analyse tumour samples for a range of relevant molecular markers that will help direct cancer drug treatment.
 - There must be clear patient benefit
 - To develop a robust system of data management to permit easy access to the generated data for clinicians
-

Three proposed phases....

- Phase 1 (2011-2013):
 - Pilot study to demonstrate on a small scale how the NHS can provide molecular diagnosis for all cancer types routinely
 - Phase 2 (2013-2015):
 - Integrate lessons learned from Phase 1 into broader NHS practice
 - Phase 3 (2015+):
 - Provision of an national integrated molecular service delivering quality assured, continuously improving and cost effective tests for NHS patients
-

Phase 1



Edinburgh
Cambridge
London
Leeds
Manchester
Cardiff
Glasgow
Birmingham*

Cardiff
London
Birmingham

Technology Strategy Board

As part of an £11m programme in stratified medicines, the Technology Strategy Board is to invest up to £5.6m in collaborative research and development projects in the area of tumour profiling and data capture to improve cancer care by providing cancer specialists with information specific to the patient's tumour which will enable more targeted treatment to be provided.

Technology Strategy Board
Driving Innovation



Stratified medicines programme:
Tumour profiling and data
capture to improve cancer care

COMPETITION FOR COLLABORATIVE R&D FUNDING
JANUARY 2011



University Hospitals Birmingham 
NHS Foundation Trust

Birmingham Women's 
NHS Foundation Trust



Extending collaborations

- Rapidly expanding science and technology
 - Competitive environment
 - Engaging with private and academic sectors
 - Networks and partnerships within NHS
 - Improving patient care
-

